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Abstract
Background: Placebos play an important role in clinical trials and several surveys have shown that they are also
common in daily practice. Previous research focused primarily on the frequency of placebo use in outpatient care.
Our aim was to explore physicians’ views on the use of placebos in daily practice, whereby distinction was made
between pure placebos (substances with no pharmacological effect, e.g. sugar pills) and impure placebos
(substances with pharmacological effect but not on the condition being treated, e.g. antibiotics in viral infections
or vitamins).
Methods: We performed semi-structured interviews with a sample of twelve primary care physicians (PCPs). The
interview addressed individual definitions of a placebo, attitudes towards placebos and the participants’ reasons for
prescribing them. The interviews were transcribed and analysed using qualitative content analysis.
Results: The definition of a placebo given by the majority of the PCPs in our study was one which actually only
describes pure placebos. This definition, combined with the fact that most impure placebos were not regarded as
placebos at all, means that most of the participating PCPs were not aware of the extent to which placebos are
used in daily practice. The PCPs stated that they use placebos (both pure and impure) mainly in the case of non-
severe diseases for which there was often no satisfactory somatic explanation. According to the PCPs, cases like
this are often treated by complementary and alternative therapies and these, too, are associated with placebo
effects. However, all PCPs felt that the ethical aspects of such treatment were unclear and they were unsure as to
how to communicate the use of placebos to their patients. Most of them would appreciate ethical guidelines on
how to deal with this issue.
Conclusions: Many PCPs seem to be unaware that some of the drugs they prescribe are classified as impure
placebos. Perceptions of effectiveness and doubts about the legal and ethical aspects of the use of placebos by
PCPs may discourage their application. Dissemination of guidelines and consensus papers may be one approach,
but it has to be acknowledged that the topic itself is in conflict with the PCPs’ perception of themselves as
professional and reliable physicians.
Background
Placebos are commonly used in clinical trials and a
number of surveys have shown that they are also com-
mon in daily practice [1]. The placebo effect has been
examined in several studies [2-5]. Most physicians agree
that the placebo effect plays a significant role, but that
the use of placebos is often associated with uncertainty
regarding the ethical dimensions of whether and how to
communicate the use of a placebo to the patient.
Previous research focused mainly on quantitative
aspects, such as the frequency of prescribing placebos in
routine care. Questionnaire surveys from Denmark [6]
and Israel [7] for instance showed that more than half
of the physicians used placebos. In Denmark, 86% of the
primary care physicians had prescribed a placebo at
least once within the last year and about half of the phy-
sicians prescribe them on average once a month. How-
ever, the frequency of use in daily practice is only one
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any medium, provided the original work is properly cited.important aspect of this issue - at least as important are
the attitude, motivation and expectations of physicians.
In order to evaluate these qualitative aspects of pla-
cebo use, it is crucial to distinguish between pure place-
bos and impure placebos [8]. Pure placebos are
substances or forms of treatment that have no pharma-
cological effect, e.g. sugar pills or saline infusions.
Impure placebos have pharmacological effects, but the
effect on the specific disease the substance is prescribed
for has not been proven or is uncertain. Examples of
impure placebos are vitamin infusions in the treatment
of cancer or antibiotics for virally-caused common colds.
I nt h ep r e s c r i p t i o no fp u r ep l a c e b o st h e r ei sam o r a l
implication of “lying to the patient” and this could jeo-
pardise the doctor-patient relationship. This aspect has
frequently been criticised by ethicists. In contrast, the
prescription of impure placebos seems easier to justify
because interventions with these placebos may have
some pharmacological or physical effect which impacts
the patient’s health in a positive manner [9].
Since all previous studies - with the exception of the
qualitative study of Lynöe et al. from 1993 [10] - were
carried out on the basis of surveys, little is known about
the dilemmas, motives and uncertainties of the physi-
cians or of the legal “grey zone” or expectations regard-
ing the use of pure/impure placebos.
The aim of our study was to explore primary care
physicians’ attitudes, behaviour and experiences regard-
ing the use of placebos in a qualitative approach. We
explored whether, how and why they prescribe placebos
in daily practice. Furthermore, we aimed to identify
potentially significant distinctions that practising clini-
cians make between the prescription and legitimacy of
pure vs. impure placebos.
Methods
Sampling
A non-randomised, convenience sample of practising
PCPs from a region in Switzerland was used. PCPs were
recruited during a symposium which did not focus on
issues of placebo use. The symposium was organised by
the Institute of General Practice and Health Services
Research at the University of Zurich. A leaflet was dis-
tributed describing the aim of the study. Fourteen pri-
mary care physicians enlisted their names and addresses,
most of them practising in or around Zurich. Of these
participants, twelve were from rural practices and only
two from urban ones.
Interviews
We developed a semi-structured interview guide with
open-ended questions that were categorised into six
main domains (shown in Additional file 1).
Before starting the interviews, a pre-test was per-
formed to ensure content validity of the interview guide.
The interviews were conducted by RF during the period
April - July 2009 at the physicians’ own practice loca-
tions. No specific definition of the term “placebo” was
given, since we intended to investigate how the physi-
cians defined it themselves. Each interview lasted about
30 minutes and was recorded digitally. The interviewer
ensured that every question was well understood and
double-checked replies that were not entirely clear in
order to avoid queries or misunderstandings later on.
Where necessary, the interviewer asked additional ques-
tions to clarify the participant’s opinion.
Questions
Physicians were asked about their attitude, behaviour
and experiences regarding the use of placebos as sug-
gested in the moderator’sg u i d e .T h e yw e r ea s k e d
whether, how and why they use placebos in their daily
practice, what they communicate to the patient, how
they deal with the moral aspects of using placebos and
whether they thought there was a need for recommen-
dations or guidelines on the use thereof.
Analysis
Without disclosing the identities of the participants, the
interviews were transcribed literally and subsequently
analysed according to the qualitative content analysis of
Mayring [11]. ATLAS.ti-software [12] helped to code
the interviews. Before starting the analysis, we estab-
lished an initial categorising system based on the mod-
erator’s guide (shown in Table 1). During the process of
analysis, categories were consistently modified and/or
supplemented with (sub-) categories. In addition, a free
category was created from the text and incorporated
into the categorising system. With a view to heightening
the objectivity of categorising and coding, the transcrip-
tions were read and analysed by two coders (one
Table 1 Coding system
Themes and Categories Subcategory (1) Subcategory (2)
1. Physicians’ definition of
placebo and explanation of
placebo effects
2. Experiences with placebo
use
3. Placebo use in daily practice Pure placebos Impure placebos
4. CAM as placebo treatment Phytotherapy Homeopathy
5. Communication with the
patient/Ethical issues
6. Need for guidelines
7. Further remarks
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results were then compared. There were no notable dis-
crepancies in the selection of relevant quotes or in cod-
ing. Minor differences in the two analyses were
discussed between the coders and common agreement
on coding was reached. After coding the interviews with
ATLAS.ti, the program also allowed the content-analysis
of the participants’ opinions on the use of placebos.
Quotes that were selected to be shown in the results
section were translated in advance.
Ethics or Ethical approval
The Research Ethics Committee of the Canton of Zur-
ich, Switzerland, approved the study. All information
was treated confidentially.
Results
Twelve of the fourteen enlisted primary care physicians
finally agreed to participate. Our study sample consisted
of eight general practitioners, two internists, one paedia-
trician and one psychiatrist. On the basis of the Swiss
health care system, these practitioners can all be classi-
fied as primary care providers. The age of the partici-
p a n t sr a n g e df r o m4 5t o6 6y e a r sw i t ham e a na g eo f
56 years, as shown in Table 2. Two out of twelve inter-
viewed physicians were women.
Theme 1: Definition of placebo
We asked physicians to state in their own words their
definition of placebo and of the placebo effect, their atti-
tude towards placebos and their own explanation of how
they might work. When asked about how they would
define the word “placebo”, the majority of PCPs stated
that a placebo is a dummy drug without substance.
Some commented that a placebo does not necessarily
need to be a pill, but can also be an injection or treat-
ment. All but one of the interviewed PCPs discussed
only pure placebos, and only one mentioned that there
are different kinds of placebos, distinguishing pure from
impure placebos, defining this as follows:
‘There are true placebos that have some random fan-
tasy name and have nothing in them, and then there are
impure placebos, for example vitamin compounds, that
may have some effect, but one prescribes them intending
to induce a placebo effect.’ (PCP 12, male, 59 years)
It can thus be deduced that the majority of PCPs are
not sufficiently informed to distinguish between pure
and impure placebos and that they are not aware of the
(impure) placebo effect of vitamins or antibiotics.
In addition, physicians’ statements clearly indicated an
ambivalent attitude toward placebos. For example, one
PCP said: ‘I would say the effect is both positive and
negative. I think that a GP consultation in itself often
creates a placebo effect without the physician even being
aware of it. Our authority, charisma or empathy are
often a lot more effective than the medication we pre-
scribe. The negative aspect, on the other hand, is that I
feel as if I am deceiving the patient or not confronting
him with the truth.’ (PCP 8, female, 58 years)
PCPs are very ambivalent in their evaluation of the
placebo effect. On the one hand, they emphasised the
supplemental benefit of the placebo effect in every treat-
ment. On the other hand, they mentioned the negative
aspect of placebo use. PCPs are aware of the fact that
they have a great deal of latitude in providing placebo
treatment without patient consent. Due to this lack of
consent, the physicians often associated placebo use
with deception of the patient and thus viewed the pre-
scribing of placebos as problematic. They emphasised
the negative aspect of feeling that they were lying to
their patients.
Theme 2: Experience with placebo effects
The category “experience” reflects physicians’ experi-
ences with the use of placebos and provides information
as to whether they have ever observed a placebo effect
in their daily practice. All PCPs stated that placebo
effects do exist. Nevertheless, many PCPs deny ever hav-
ing observed a placebo effect in their own daily practice.
In the course of the interview, however, many of them
reported several specific situations in which a placebo
effect had occurred. The physicians were not aware of
this effect. They underestimated the possible impact of
placebos in their daily practice.
For example, one primary care physician reported
cases where patients felt immediate relief from their
complaint following an injection with lidocaine and cor-
tisone, although pharmacologically, the medication can-
not act that quickly.
‘So, for example, when a patient comes to me with tor-
ticollis, i.e. with strained neck muscles, and I give him
Table 2 Details of the interviewed practitioners
Specialisation Sex Age
General medicine Male 45
General medicine Male 48
Internal medicine Male 50
General medicine Female 54
General medicine Female 58
Internal medicine Male 59
General medicine Male 60
General medicine Male 62
General medicine Male 62
General medicine Male 66
Paediatrician Male 54
Psychiatry, Homeopathy Male 56
Fent et al. BMC Family Practice 2011, 12:11
http://www.biomedcentral.com/1471-2296/12/11
Page 3 of 7an injection of lidocaine with a little cortisone, I have
often observed that as soon as the injection has been
administered and the patient has been escorted outside,
he reports feeling that the injection has already taken
effect and that his ability to move has improved. The
same has also been observed with regard to lower back
pain. Well, in my opinion, the drug cannot act so fast.’
(PCP 7, male, 45 years)
Theme 3: Use of placebos among PCPs with placebo
experience
“Placebo use” as a category included physicians’ state-
ments about the use of both actual placebos and of pla-
cebos in the form of complementary and alternative
medicine (CAM) in their daily practice.
Subtheme: Use of placebos in daily practice
PCPs expressed ambivalence towards using placebos in
daily practice. On the one hand, most of them believed
that placebos provide beneficial treatment. On the other
hand, they were often concerned about what to tell the
patient. Nearly all were afraid of the potential harm of
deception. When asked whether there are specific situa-
tions (disease- or patient-specific characteristics) in
which they use placebos, all physicians stated that the
response to placebos varies according to clinical condi-
tion or gender. They use placebos most often when they
believe the patient has a less serious or psychogenic dis-
order. PCPs named fractures or malignant tumours as
examples in which they believed placebos would not
work at all. They tend to use placebos in particular in
situations where a strong psychological strain is
assumed. Other reasons given were “to calm the patient
down” and to avoid adverse drug reactions. Some of
them stated that women respond better than men or
children. One primary care physician stated that intelli-
gence has no influence on the placebo effect.
Only two physicians affirmed having sugar pills in
stock in order to use them as placebos. Two PCPs said
that they use saline injections for patients with rheu-
matic complaints who request an injection against the
pain. Other PCPs argued in favour of using placebos in
order to avoid drug addiction to pain killers or sleeping
pills. One PCP emphasised that he only uses pure place-
bos on patients he has known for a long time and who
he judges to be suitable for such treatment. Further-
more, it was interesting that two PCPs used pure place-
bos in a diagnostic procedure to investigate the origin
or the nature of the particular disease.
The physician’s decision on whether to use an impure
placebo is based, on the one hand, on his perception of
the patient’s expectation to be given “something” for his
complaint and, on the other, his conviction that patients
should take responsibility for their own health and be
aware that not all complaints can be by taking a pill.
‘I prefer to administer placebos in liquid form. For
example, if a patient comes to me with a mental pro-
blem and I do not yet consider psychiatric drugs to be
necessary, I hand him a glass of water, telling him that
it contains a substance that will calm him down. Some-
times I have observed that a patient will actually calm
down a little.’ (PCP 4, male, 62 years)
‘People come and expect me to give them something.
Although I know that what I am giving them won’t really
help, I feel I have to do something rather than nothing
and what I give them certainly won’t do them any harm’
‘ (PCP 5, male, 54 years)
Some PCPs reported a strong need on the part of
patients to be taken seriously. Patients expect the physi-
cian to administer a drug and not to simply do nothing.
Subtheme: CAM as placebo treatment
Eleven of the twelve physicians stated that they use phy-
totherapy, homeopathy or both. Phytotherapy was con-
sidered to produce both pharmaceutical and substantial
placebo effects. In contrast to this, eight PCPs stated
that homeopathy works solely by placebo effect:
‘I think phytotherapy is also a form of pharmacological
therapy, simply not with pure substances. There is classi-
cal homeopathy, where I think the patient’sf e e l i n go f
being cared for and the relationship to the physician
account for much of the effect. And then there is also
‘over-the-counter homeopathy’ at the pharmacy, in which
I think that the placebo effect is much more important.
(PCP 5, male, 54 years)
The effect of homeopathy was seen as a result of a
good doctor-patient relationship built on respect and
trust of the physician, thus improving health outcomes.
Theme 4: Communication with the patient
We defined “communication with the patient” as the
way in which the PCP communicates with the patient
when he uses a placebo and how the PCP deals with the
moral aspect of doing so, in particular with his percep-
tion of “lying” to the patient. The majority of the PCPs
in the study only gave their patients vague and very gen-
eral information when they used placebos. They claimed
to be in a conflict. On the one hand, they avoided going
into detail since they did not want to lie to the patient -
lying was presumed to place a substantial burden on the
doctor-patient relationship. On the other hand, they did
not want to reduce the placebo effect by telling the
patient too much or using the word “placebo” itself.
One physician stated that he preferred to give placebos
and lie to the patient than to give medication that
would work equally well, but have adverse effects.
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tifies the means’ and sometimes I also tell people that
certain medication might have an additional effect if one
believes in it, or also the quote ‘If it does not hurt, it
won’t do any harm either’. Sometimes it can be seen
from this point of view too. But I don’t say to the
patients, ‘Here, this is not real medication, but perhaps if
you believe in it, it will help.’ If you do that you’ll cer-
tainly ruin everything. If you declare medication as not
being real, there won’t be any placebo effect at all.’ (PCP
10, male, 62 years)
Theme 5: Need for guidelines
Physicians were asked their opinion as to whether they
believed guidelines on the use of placebos would be
helpful. The ethical dilemma was obvious throughout
the interviews. Nevertheless, the interviewed PCPs were
divided regarding the question as to whether guidelines
should be developed. Some of them did not believe they
were warranted since they were still convinced that their
methods of treatment were based mainly on pharmaceu-
tical effects and that the placebo effect just provided an
unavoidable additional effect. Physicians believe that the
presence of guidelines implies a lack of integrity. In con-
trast, more than half of the interviewed physicians
declared that they would welcome wider discussion on
the use of placebos in practice.
‘I think recommendations and guidelines aren’tb a d .
We always like guidelines. It is good for us if we know
what should be done. That certainly wouldn’tb eb a d . ’
(PCP 3, female, 54 years)
‘To my knowledge there’s nothing. I think it would
make sense if we would discuss the ethical aspects once
in a while and define under what circumstances it (pla-
cebo use) would be compatible with a medical attitude.’
(PCP 6, male, 60 years) Recommendations were seen as
an adequate way to deal with physicians’ ambivalent
attitude toward the use of placebos. Guidelines or at
least consensus papers would ease the perceived ethical
dilemma.
Discussion
Definition
One of the main findings of our study is that the pla-
cebo effect is not always recognised by physicians since
their definition of placebo is often restricted to what is
formally defined as a pure placebo (‘...it is a dummy
drug without substance.’). In placebo literature, a variety
of different definitions can be found. For example, one
publication defined the placebo as “as h a mt r e a t m e n t ,
such as a pill, liquid, or injection without biological
activity, used in pharmacology to control for the activity
of a drug. However, in many cases this placebo induces
biological or psychological effects in the human” [13].
Another publication defined the placebo intervention as
“any therapeutic procedure that has an effect on a
patient, symptom, syndrome or disease, but which is
objectively without specifica c t i v i t yf o rt h ec o n d i t i o n
being treated” [14]. Both definitions describe a placebo
as something that produces placebo effects. In contrast
to these wider definitions, the PCPs in our qualitative
study defined placebos more narrowly as pharmacologi-
cally inactive substances. These definitional differences
present a considerable challenge with regard to con-
structive professional discourse on the role of placebos
in clinical practice. It is also important to find a standar-
dised definition of the effect of placebo treatment in
order (1) to accurately evaluate the effect of any drug
therapy, (2) to compare study results with each other,
and finally (3) to draw conclusions about the overall
effect of placebo interventions, for example in a sys-
tematic review.
Experiences and awareness
Many physicians reported several specific situations in
which they encountered placebo effects (‘... I hand him
a glass of water, telling him that it contains a substance
that will calm him down. Sometimes I have observed
that a patient will actually calm down a little.’).T h i s
finding seems to be consistent with results from quanti-
tative surveys examining the frequency of placebo use,
although we are aware of the fact that the focus of these
surveys was completely different from ours (qualitative
vs. quantitative approach). For example, studies from
Denmark [6] and Israel [7]reported that more than half
of the physicians use placebos. In Denmark, 86% of the
PCPs prescribed a placebo at least once within the last
year and about half of the physicians on average once a
month.
Interestingly, many of the interviewed PCPs initially
denied that they have observed a placebo effect. But in
the course of the interviews, most of them reported
situations in which a placebo effect had occurred. PCPs
were not aware that some of the drugs they use are clas-
sified as impure placebos.
Use of Placebos in daily practice
All physicians stated that the response to treatment with
a placebo differs according to the nature of the illness
and that placebos were mainly used for psychosomatic
symptoms.
There is evidence that patients suffering from pain or
depression respond particularly well to placebos [15],
whereas patients treated for cancer, nervous diseases
and substance abuse seem to have a lower than average
response [16]. A study of placebo use in lower urinary
t r a c ts y m p t o m ss h o w e dt h a tt r i a l sa s s e s s i n gs u b j e c t i v e
outcomes generally record higher placebo effects than
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tron emission tomography (PET)) [17]. This means that
the effect of treatment with a placebo on the patients’
subjective feeling of being unwell is greater than the
actual objectively measurable healing effect is.
CAM as placebo treatment
Interestingly, complementary and alternative medicine
were mentioned in this context by all PCPs. Most physi-
cians agreed that phytotherapy has both important
placebo and pharmaceutical effects. Traditional homeop-
athy has also been strongly equated with placebo effects
(‘...there is classical homeopathy, where I think the
patient’s feeling of being cared for and the relationship
to the physician account for much of the effect...’).
Regarding the different situations in which patients
respond to placebo treatments, Kaptchuk et al. [18] con-
cluded in their review that the evidence is too weak to
support the existence of ‘placebo responders’. Such pla-
cebo responders could be patients with a particular dis-
order who respond well to the administering of a
placebo and will also respond to the repeated adminis-
tering of similar placebos under similar conditions.
A placebo responder could also be a person who
responds to a placebo in one situation and will also
respond in another situation or when using a different
type of placebo ritual. The PCPs in our study stated
that, according to their observations, they can identify
particular characteristics of patients likely to respond to
placebo treatment.
Women and patients with psychosomatic disorders
were mentioned as likely responders, a finding which
has already been reported by Chaput de Saintonge et al.
[19] in patients with anxiety disorder.
Interestingly, all primary care physicians emphasised
t h er o l eo fp a t i e n t s ’ positive expectations, but none
mentioned that conditioning is also an important factor,
as the current main theory suggests: The placebo effect
is perceived on the basis of unconscious conditioning
and conscious expectations [13].
Communication with the patient
Most primary care physicians had a conflict concerning
the use of placebos when contrasting the beneficial pla-
cebo effect with the aspect that placebos only work
when they avoid telling the patient about the placebo
procedure (‘Id o n ’t like lying to people, but sometimes
‘the end justifies the means’...’). Since PCPs were aware
of such deception and of thus being in a legal grey zone,
they gave the patient only general information in situa-
tions in which they used placebos. The PCPs stated that
if patients had known that they were being treated with
placebos, the placebo would not have been effective.
Biller-Andorno suggest a way to use placebos with
informed consent by building up a trusting doctor-
patient relationship [9]. A recent article summarised the
results of open-label placebo treatment [20]. The article
concluded that experiments suggest the possibility of
clinically significant benefit of prescribing placebos with-
out deception, although questions remain about efficacy.
In contrast, a study from Pollo et al. [21] showed that
response to expectancies is a major determinant of pla-
cebo effects. Both studies indicated that deception might
not be necessary to promote a placebo response, but
more studies in a practice setting are needed to verify
this. In placebo-controlled studies, subjects know that
they might be given a placebo, but in clinical practice,
patients assume that they are being treated with active
medication. One suggestion as to how to inform the
patients is “to provide a neurobiological explanation,
describing the placebo as a harmless agent, whose
administration is meant to bring about improvement in
the disorder” [22]. Chaput de Saintonge et al. [19] and
Lichtenberg et al. [23] discuss further approaches to
using placebo treatment.
Guidelines
PCPs also expressed ambivalence as to whether the dis-
semination of ethical guidelines would be helpful. Those
who accepted the placebo effect as an important part of
medical therapy would appreciate consensus papers or
guidelines, whereas some other PCPs stated that the use
of placebos should not be regarded as professional beha-
viour and that guidelines would ignore the individuality
of each patient. In the US, for example, the American
Medical Association’sr u l i n go np l a c e b o sp r o v i d e s
recommendations on placebo use in clinical practice
which “respect patients’ autonomy by allowing them to
participate actively in the medical decision-making pro-
cess.” [24]. Such recommendations might be an
approach to reduce uncertainties in dealing with place-
bos in daily practice.
Limitations
Some limitations of this stu d yh a v et ob ec o n s i d e r e d .
The aim of qualitative studies is to generate ideas and
hypotheses. Due to this methodological approach, quan-
titative conclusions cannot be drawn. Additionally, it is
important to emphasise that the statements in our inter-
views reflect self-reported behaviour, which may not
reflect reality. It is also important to recognise a poten-
tial selection bias, because the interviewed PCPs were
recruited after having indicated their interest in the
topic. Furthermore, our sample is geographically
restricted and as such not representative of larger popu-
lations. The sample consisted predominantly of rural
physicians. However, several studies have shown that
there are no differences between physicians from rural
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tice was assumed not to influence the outcome
[8,10,25]. Moreover, the term “placebo” itself, mentioned
at the beginning of the interview, may bias physicians
and influence the way PCPs describe the role of place-
bos in their daily practice.
T oo u rk n o w l e d g e ,t h i si st h ef i r s ts t u d yt og i v ea
detailed understanding of the use of placebos in primary
care using a qualitative analysis of primary care physi-
cians’ narratives.
Conclusions
Many PCPs seem to be unaware that some of the drugs
they use are classified as impure placebos. Both effec-
tiveness and legal and ethical aspects seem to interfere
substantially with placebo use. Dissemination of guide-
lines and consensus papers may be an approach but it
has to be acknowledged that the topic itself is in conflict
with the PCPs’ perception of themselves as professional
and reliable physicians.
Additional material
Additional file 1: Interview guide. The used interview guide translated
in English.
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